Do polygenic risk scores add to clinical data in predicting pancreatic cancer? a scoping review.
Louise L WangAlyssa A GrimshawCatherine MezzacappaNavid Rahimi LarkiYu-Xiao YangAmy C JusticePublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2023)
For PC PRS to be clinically useful, they must demonstrate substantial improvements in discrimination beyond established risk factors, apply to diverse ancestral populations representative of those at risk for PC, and use appropriate controls.